BAY 1161909 (Empesertib) is primarily investigated for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and survival. It functions as an inhibitor of certain kinases that play a critical role in cell proliferation and DNA damage response. This makes it a promising candidate for treating various cancers, especially those with defects in DNA repair mechanisms, such as certain types of breast and ovarian cancers. Research is ongoing to explore its efficacy in combination with other therapies, aiming to enhance treatment outcomes and overcome resistance to existing drugs. Clinical trials are evaluating its safety, tolerability, and effectiveness in patients, with a focus on optimizing dosing regimens and identifying suitable patient populations.